Development asset linked to Chiesi Australia Pty in public FDA and regional records.
pharma
Chiesi Australia Pty
Chiesi Australia Pty Ltd
Chiesi Australia Pty drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Hawthorn East, AU HQ
TGA registrant Type
Company details
- Status
- Public
- HQ
- Hawthorn East, AU
- Programs
- 0
- Drugs
- 5
- Patents
- 0
Chiesi Australia Pty pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chiesi Australia Pty drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Calcitonin receptor.
- Target
- Calcitonin receptor
- Mechanism
- Calcitonin receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
deferiprone
Various (V03)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
stiripentol
Nervous system (N03)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown